Static Image
FDA Approves Two New Drugs for Psoriatic Arthritis

FDA Approves Two New Drugs for Psoriatic Arthritis

Good news for the approximately two million Americans with psoriatic arthritis (PsA). Those with active disease now have two new treatment options: the U.S. Food and Drug Administration (FDA) in December approved both ixekizumab (Taltz) and tofacitinib (Xeljanz) for the treatment of PsA. This is the second approved indication for ixekizumab. The biologic, which is injected, was approved in March 2016 to treat moderate-to-severe plaque psoriasis in adults. It can be taken alone or in combination with a traditional disease-modifying antirheumatic drug (DMARD), such as methotrexate. This is also the second approved indication for tofacitinib, a so-called targeted DMARD that is taken ...more
Researchers on the Path to a Cure – Spotlight on Dr. Caroline Jefferies

Researchers on the Path to a Cure – Spotlight on Dr. Caroline Jefferies

Lupus is a chronic, autoimmune disease and affects a wide part of the body, including the joints, kidneys, skin, blood, brain and other organs. One of our six Delivering on Discovery projects focuses on Lupus and lung disease. “Lupus is a complex disease. It affects many organs. The number of lupus patients with lung inflammation is probably underestimated. Yet it negatively impacts the quality of life in these patients,” explained Dr. Caroline Jefferies. “And while we have a basic understanding about how lupus affects various organs, we need to better understand how it affects the lungs to better manage and ...more
Synvisc-One Injections Recalled

Synvisc-One Injections Recalled

Biotech giant Sanofi Genzyme has initiated a voluntary product recall for one lot of Synvisc-One, a brand of hyaluronic acid. The lot, which was found to contain contamination, has been linked to an unexpected increase in side effects. In an urgent “product hold” letter, doctors, clinics and pharmacies who received syringes from that lot were instructed to immediately stop using the injections on patients until the company can investigate. “The voluntary product recall of one (1) lot of Synvisc One, lot 7RSL021, is due to an ongoing investigation which revealed the presence of microbial contamination,” said Sanofi spokesperson Heather Guzzi in ...more
Raquel Masco: Working Through the Pain

Raquel Masco: Working Through the Pain

Raquel Masco is no stranger to making the most out of a difficult situation. In fact, she’s made an entire career from dusting herself off and getting back on her feet. After leaving an unhealthy relationship to raise her child alone, Raquel decided she would help others in similar situations. She co-founded the nonprofit SingleMothers4Change and has spent the last several years ensuring single moms in her Texas community have the resources they need to build an amazing life. With her can-do attitude, it’s no surprise that an arthritis diagnosis didn’t keep her down. She’s determined to make the best of ...more
Study Finds Many More U.S. Adults Have Arthritis Than Previously Thought

Study Finds Many More U.S. Adults Have Arthritis Than Previously Thought

Arthritis might be far more common in the United States than previously thought, especially among adults younger than 65. That’s according to a new study published online in Arthritis & Rheumatology in November. Researchers at Boston University School of Medicine (BUSM) undertook the study because they suspected the current estimate from the Centers for Disease Control and Prevention (CDC) – which puts the number of adults with arthritis in the U.S. at around 54 million – might be too low. That estimate is based on a single question on the National Health Interview Survey (NHIS) that asks whether survey participants have “ever ...more
An Early Look at the New Psoriatic Arthritis Treatment Guideline

An Early Look at the New Psoriatic Arthritis Treatment Guideline

Physicians will soon have a new guideline for the management of psoriatic arthritis (PsA). This ambitious undertaking, the details of which were presented recently at the American College of Rheumatology (ACR) Annual Meeting, involved a large panel of experts who analyzed and synthesized the best available evidence to create and support the recommendations. The proposed guideline – which contains approximately 80 recommendations – will undergo final review prior to consideration for publication in 2018 in the journals Arthritis Care & Research and Arthritis & Rheumatism. It will help rheumatologists select treatments for their psoriatic arthritis patients based on the best available evidence, especially in light of all the new treatments recently approved for PsA by the Food and Drug Administration (FDA). A Need for a PsA Guideline?  “ had formal guidelines for PsA before, but now we have a lot of new treatment options for the management of this disease,” says Jasvinder Singh, MD, head of the panel ...more
Researchers on the Path to a Cure – Spotlight on Dr. Edward Doherty

Researchers on the Path to a Cure – Spotlight on Dr. Edward Doherty

Why is my immune system attacking my joints? What is the cause? If you have rheumatoid arthritis (RA), this is something you have probably wondered at some point. It’s something Dr. Edward Doherty has wondered as well, and is currently studying. Dr. Doherty and his co-investigator, Dr. Pathricia Tilstam are studying key cells that drive inflammation in their 2-year Arthritis Foundation-funded project, “MIF/CD74 signaling as a new candidate for immunotherapy of rheumatoid arthritis”. With autoimmune disorders like RA, something triggers the immune system to malfunction and attack healthy cells, causing inflammation and disease. Dr. Doherty and Dr. Tilstam are looking ...more
Become a PARTNER to Help Find a Cure

Become a PARTNER to Help Find a Cure

Juvenile arthritis (JA) affects nearly 300,000 kids and families in the United States. Of all the forms of arthritis, juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children. For almost seven decades, the Arthritis Foundation has upheld our unwavering promise to assist them and their caregivers. In an ongoing effort to include the patient voice in everything we do, we’re asking you – patients, parents, loved ones and others with a connection to JIA – to tell us what JIA research matters to you. The Arthritis Foundation is a member of PARTNERS, a network of patients, parents, ...more
Platinum Ambassador Spotlight—Rebecca Gillett, Colorado

Platinum Ambassador Spotlight—Rebecca Gillett, Colorado

In 2016, I was fortunate to attend the Arthritis Foundation Advocacy Summit in Washington D.C. alongside some seasoned advocacy veterans from Denver. I had never met with my legislators or shared my story before, so it was a new experience. It was easy to “catch the bug” for advocacy being surrounded by so many other fellow arthritis patient advocates who want to make a difference for all of us. Raising awareness and fundraising for arthritis has been an integral part of my life for the past several years, but advocacy has become an even greater passion. This year, I achieved ...more
Year-End Tax Planning in Uncertain Times

Year-End Tax Planning in Uncertain Times

There is always a certain degree of guesswork that goes into year-end tax planning, but this year there is the added uncertainty surrounding what the tax code will look like after Washington completes the overhaul of our tax system.  The income tax rates for many individuals and businesses may decrease; the definition of income subject to tax may change considerably as well.  Many itemized deductions that we have become so used to, such as the deduction for qualified medical expenses, state and local income taxes and real estate taxes may be eliminated. However, if the resulting new rules resemble the proposals, ...more